Cellular Biomedicine Group Commences Trading of Its Common Stock on The NASDAQ Capital Market
June 18 2014 - 8:00AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"), a
biomedicine firm engaged in the development of new treatments for
degenerative and cancerous diseases, announced today that its
common stock commences trading on NASDAQ under the ticker symbol
"CBMG" effective today, June 18, 2014.
"We are extremely proud to be an early pure-play biotechnology
company from China to be approved for listing on The NASDAQ Capital
Market and are gratified to have reached this significant milestone
in the Company's history. We believe this achievement will provide
greater visibility for our stock and that this accomplishment
demonstrates to our shareholders our commitment to building
shareholder value while improving the quality of life for countless
patients," stated Dr. Wei (William) Cao, Chief Executive Officer of
Cellular Biomedicine Group.
Mr. Bizuo (Tony) Liu, Chief Financial Officer of Cellular
Biomedicine Group, commented, "Following a comprehensive evaluation
of all U.S. exchanges, we determined that The NASDAQ Capital Market
was the best fit for Cellular Biomedicine Group. CBMG has met and
will remain subject to all the NASDAQ listing requirements."
The NASDAQ Capital Market is the largest U.S. equities exchange
by number of companies and volume, with approximately 3,200
member-companies. Nasdaq-listed companies are leaders across all
areas of business including biotechnology, industrials, technology,
retail, communications, financial services, transportation, and
media.
Ellenoff Grossman & Schole LLP (www.egsllp.com), a leading
securities law firm specializing in small and mid-cap public
companies, represented Cellular Biomedicine Group in connection
with its listing on The NASDAQ Capital Market.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. The Company's developmental stem cell, progenitor cell,
and immune cell projects are the result of research and development
by scientists and doctors from China and the United
States. The Company's flagship GMP facility, consisting of eight
independent cell production lines, is designed, certified and
managed according to U.S. standards. To learn more about
CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 646-284-9427
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024